Table 1

Cohort characteristicsa

Cohort

Patients (n = 214)

Controls (n = 31)


MBL genotype group A, n (%)

114 (53.3)

16 (51.6)

MBL genotype group B, n (%)

59 (27.6)

8 (25.8)

MBL genotype group C, n (%)

41 (19.2)

7 (22.6)

Number of Caucasians, n (%)

207 (96.7)

31 (100)

Number of nulliparous women, n (%)

113/214 (52.8)

14/31 (45.2)

Mean age at delivery, yr (± SD) (range)

32.5 ± 3.7 (21.9 to 40.6)

32.1 ± 4.5 (24.2 to 40.1)

Mean gestational age at delivery, wk (range)

39.4 (31.4 to 42.1)

40.0 (34.7 to 42.0)

Smoking during pregnancy, n (%)

6/206 (2.9)

3/31 (9.7)

Miscarriage, n (%)

23 (10.7)

-

Hypertension, n (%)

25/210 (11.7%)

2 (6.5)

Preeclampsia, n (%)

4/210 (1.9)

1 (3.2)

Anti-CCP-positive, n (%)

134/213 (62.9)

-

Rheumatoid factor (IgM)-positive, n (%)

161/214 (75.1)

-

Erosive disease, n (%)

136/210 (64.8)

Median disease duration at delivery, yr (range)

7.9 (0.7 to 29.0)

-

Use of prednisone in first trimester, n (%)

60/164 (36.6%)

Median number of DMARDs (including prednisone) prior to conceive (min-max)

2.3 (0-6)

-

Use of methotrexate prior to conception, n (%)

120/212 (56.6)

-

DAS28-CRP3 >3.2 in first trimester, n (%)

84/155 (54.2)

-

Classification of disease activity during pregnancy

Good response or moderate response, n (%)

40/84 (47.6)

-

No response, n (%)

44/84 (52.4)

-

Classification of disease activity during postpartum period (early flare)

Severe or moderate deterioration, n (%)

39/167b (23.4)

-

No deterioration, n (%)

128/167b (76.6)

-

Classification of disease activity during postpartum period (late flare)

Severe or moderate deterioration, n (%)

28/152b (10.3)

-

No deterioration, n (%)

124/152b (45.6)

-


aMBL, mannose-binding lectin; n, number; SD, standard deviation; anti-CCP, anti-cyclic citrullinated peptide; IgM, immunoglobulin M; DMARDs, disease-modifying antirheumatic drugs; DAS28-CRP3, Disease Activity Score 28 using three variables, including C-reactive protein; bcases are missing because DAS score data are missing in a proportion of patients.

van de Geijn et al. Arthritis Research & Therapy 2011 13:R10   doi:10.1186/ar3231

Open Data